Aurinia Pharmaceuticals will host its Annual General Meeting on June 14th. CEO Peter Greenleaf’s total compensation includes a salary of US$822.9k, which is 157% higher than the industry average. Despite a 34% growth in EPS over the past three years, total shareholder loss during the same period was 59%.
Shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) have seen a decline in share price over the past three years, despite positive EPS growth. This discrepancy may raise concerns among shareholders, who have the opportunity to address these issues at the upcoming AGM on June 14th. They can vote on resolutions, such as executive remuneration, to influence management and company direction.
Comparing Aurinia Pharmaceuticals Inc.’s CEO compensation with the industry, data shows that CEO Peter Greenleaf’s total annual compensation is US$11m, which is higher than the industry median of US$4.1m for companies in the American Biotechs industry. Greenleaf also holds US$1.7m worth of Aurinia Pharmaceuticals stock.
Aurinia Pharmaceuticals Inc. has shown positive growth, with EPS growing 34% per year over the last three years and revenue up 30% in the last year. However, shareholders have experienced a -59% return over three years, indicating a need for caution when considering CEO compensation.
In summary, shareholders may have concerns about the lack of share price growth despite positive earnings growth. These concerns should be addressed at the upcoming AGM, where shareholders can question the board and evaluate the company’s performance. It is important for investors to keep an eye on CEO compensation and other issues related to business performance. Additionally, investors should be aware of any warning signs, such as the one identified for Aurinia Pharmaceuticals, and consider exploring other investment opportunities.